The intrinsic coagulation pathway plays a dominant role in driving hypercoagulability in ANCA-Associated Vasculitis.

The risk of a venous thrombotic event (VTE) is increased in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), however, a detailed understanding of the underlying mechanisms of hypercoagulability is limited. We assessed prospectively different coagulation parameters in 71 patients with active AAV at baseline and after 6 months of follow-up. D-dimers and fibrinogen were increased in most patients at presentation and remained elevated in half of the patients. Particularly thrombin:antithrombin (T:AT) and activated coagulation factors in complex with their natural inhibitors of the intrinsic coagulation pathway (i.e., activated FXII:C1 esterase inhibitor [FXIIa:C1Inh], FXIa:AT and FXIa:alpha1-antitrypsin [FXIa:α1AT]) were profoundly elevated in patients at baseline. Thrombin formation was dominantly correlated with coagulation factors of the intrinsic pathway (i.e., FXIIa:AT, FXIa:AT, FXIa:α1AT and FXIa:C1Inh) compared to the extrinsic pathway (i.e., FVIIa:AT). Hypercoagulability correlated with higher disease activity, ANCA levels, C-reactive protein, serum creatinine and proteinuria. VTE were observed in 5 out of 71 (7%) patients within one month (IQR, 1-5) after inclusion. Baseline T:AT levels were significantly higher in patients with vs. without VTE (P=0.044), but other clinical or laboratory markers were comparable between both groups. Hypercoagulability is dominantly characterized by activation of the intrinsic coagulation pathway and elevated D-dimers in active AAV. The driving factors of hypercoagulability are yet to be studied, but are most likely related to an interplay of increased disease activity, vascular inflammation, and endothelial damage. Future targets for intervention could include inhibitors of the intrinsic coagulation pathway and compounds specifically reducing the hyperinflammatory state.